Transforming Growth Factor-beta Induced by Live or Ultraviolet-inactivated Equid Herpes Virus Type-1 Mediates Immunosuppression in the Horse

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 1997 Apr 1

PMID 9176113

Citations 6

Authors

S Charan

K Palmer

P Chester

A R Mire-Sluis

A Meager

N Edington

Affiliations

Soon will be listed here.

Abstract

Up to 21 days after exposure to live or ultraviolet-inactivated equid herpesvirus type-1 (EHV-1) autologous serum from ponies caused an immunosuppressive effect if incorporated into T-cell proliferation assays to EHV-1. The suppressive factor in the sera of ponies also inhibited T-cell response to phytohaemagglutinin. Increased levels of circulating activated transforming growth factor-beta 1 (TGF-beta 1) were detected, and the suppressive activity of the serum could be reversed by antibody to TGF-beta 1. In a challenge experiment the ponies which exhibited circulating TGF-beta 1 activity succumbed to infection while the ones with similar magnitudes of T-cell responses, but no TGF-beta 1 activity, were protected. A definition of this immunosuppressive mechanism and its mode of induction must be central to the design of vaccines and to an understanding of the pathogenesis of EHV-1.

Citing Articles

Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses.

Giessler K, Goehring L, Jacob S, Davis A, Esser M, Lee Y J Gen Virol. 2024; 105(5).

PMID: 38767608 PMC: 11170125. DOI: 10.1099/jgv.0.001987.

Evaluation of immune responses following infection of ponies with an EHV-1 ORF1/2 deletion mutant.

Soboll Hussey G, Hussey S, Wagner B, Horohov D, Van de Walle G, Osterrieder N Vet Res. 2011; 42:23.

PMID: 21314906 PMC: 3045331. DOI: 10.1186/1297-9716-42-23.

Validation of quantitative polymerase chain reaction assays for measuring cytokine expression in equine macrophages.

Allen C, Payne S, Harville M, Cohen N, Russell K J Immunol Methods. 2007; 328(1-2):59-69.

PMID: 17900609 PMC: 2148255. DOI: 10.1016/j.jim.2007.08.006.

Equid herpesvirus 1 infection of endothelial cells requires activation of putative adhesion molecules: an in vitro model.

Smith D, Hamblin A, Edington N Clin Exp Immunol. 2002; 129(2):281-7.

PMID: 12165084 PMC: 1906444. DOI: 10.1046/j.1365-2249.2002.01463.x.

Alpha/beta and gamma interferons are induced by infection with noncytopathic bovine viral diarrhea virus in vivo.

Charleston B, Brackenbury L, Carr B, Fray M, Hope J, Howard C J Virol. 2001; 76(2):923-7.

PMID: 11752182 PMC: 136826. DOI: 10.1128/jvi.76.2.923-927.2002.

References

Patel J, Edington N, Mumford J . Variation in cellular tropism between isolates of equine herpesvirus-1 in foals. Arch Virol. 1982; 74(1):41-51. DOI: 10.1007/BF01320781. View

Dutta S, Myrup A, Bumgardner M . Lymphocyte responses to virus and mitogen in ponies during experimental infection with equine herpesvirus 1. Am J Vet Res. 1980; 41(12):2066-8. View

Mumford J, Bates J . Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 2 virus. Vet Rec. 1984; 114(15):375-81. DOI: 10.1136/vr.114.15.375. View

Bridges C, Edington N . Innate immunity during Equid herpesvirus 1 (EHV-1) infection. Clin Exp Immunol. 1986; 65(1):172-81. PMC: 1542268. View

Mumford J, Rossdale P, Jessett D, Gann S, Ousey J, Cook R . Serological and virological investigations of an equid herpesvirus 1 (EHV-1) abortion storm on a stud farm in 1985. J Reprod Fertil Suppl. 1987; 35:509-18. View

Flanders K, Roberts A, Ling N, Fleurdelys B, Sporn M . Antibodies to peptide determinants in transforming growth factor beta and their applications. Biochemistry. 1988; 27(2):739-46. DOI: 10.1021/bi00402a037. View

Grotendorst G, Smale G, Pencev D . Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. J Cell Physiol. 1989; 140(2):396-402. DOI: 10.1002/jcp.1041400226. View

Edington N, Bridges C, Griffiths L . Equine interferons following exposure to equid herpesvirus-1 or -4. J Interferon Res. 1989; 9(4):389-92. DOI: 10.1089/jir.1989.9.389. View

Guo P, Goebel S, Davis S, Perkus M, Languet B, Desmettre P . Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals. J Virol. 1989; 63(10):4189-98. PMC: 251033. DOI: 10.1128/JVI.63.10.4189-4198.1989. View

10.

Fontana A, Frei K, Bodmer S, Hofer E, SCHREIER M, Palladino Jr M . Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol. 1989; 143(10):3230-4. View

11.

Allen G, Bryans J . Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog Vet Microbiol Immunol. 1986; 2:78-144. View

12.

Twardzik D, Mikovits J, Ranchalis J, Purchio A, Ellingsworth L, Ruscetti F . Gamma-interferon-induced activation of latent transforming growth factor-beta by human monocytes. Ann N Y Acad Sci. 1990; 593:276-84. DOI: 10.1111/j.1749-6632.1990.tb16119.x. View

13.

Cook R, ONeill T, Strachan E, Sundquist B, Mumford J . Protection against lethal equine herpes virus type 1 (subtype 1) infection in hamsters by immune stimulating complexes (ISCOMs) containing the major viral glycoproteins. Vaccine. 1990; 8(5):491-6. DOI: 10.1016/0264-410x(90)90252-h. View

14.

Bauer G, Gotschl M, Hofler P . Tumor-promoting activity of Epstein-Barr-virus-inducing factor transforming growth factor type beta (EIF/TGF-beta) is due to the induction of irreversible transformation. Int J Cancer. 1991; 47(6):881-8. DOI: 10.1002/ijc.2910470616. View

15.

Kuruvilla A, Shah R, Hochwald G, Liggitt H, Palladino M, Thorbecke G . Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci U S A. 1991; 88(7):2918-21. PMC: 51351. DOI: 10.1073/pnas.88.7.2918. View

16.

Stokes A, Corteyn A, Pullen L, Doel T, Meredith D, Killington R . Studies on glycoprotein 13 (gp13) of equid herpesvirus 1 using affinity-purified gp13, glycoprotein-specific monoclonal antibodies and synthetic peptides in a hamster model. J Gen Virol. 1991; 72 ( Pt 4):923-31. DOI: 10.1099/0022-1317-72-4-923. View

17.

Meager A . Assays for transforming growth factor beta. J Immunol Methods. 1991; 141(1):1-14. DOI: 10.1016/0022-1759(91)90204-s. View

18.

OHagan D, Jeffery H, Roberts M, McGee J, Davis S . Controlled release microparticles for vaccine development. Vaccine. 1991; 9(10):768-71. DOI: 10.1016/0264-410x(91)90295-h. View

19.

Woodroffe S, Garnett H, Danis V . Interleukin-1 production and cell-activation response to cytomegalovirus infection of vascular endothelial cells. Arch Virol. 1993; 133(3-4):295-308. DOI: 10.1007/BF01313770. View

20.

Rinaldo Jr C, Torpey 3rd D . Cell-mediated immunity and immunosuppression in herpes simplex virus infection. Immunodeficiency. 1993; 5(1):33-90. View